Clinical Study
|
Open Access
Featured
-
-
Epidemiology
| Open AccessBody mass index in early and middle-late adulthood and risk of localised, advanced and fatal prostate cancer: a population-based prospective study
- A Discacciati
- , N Orsini
- & A Wolk
-
-
Genetics and Genomics
| Open AccessGenetic architecture of prostate cancer in the Ashkenazi Jewish population
- J Vijai
- , T Kirchhoff
- & R J Klein
-
Letter to the Editor
| Open AccessComment on ‘Hand pattern indicates risk of prostate cancer’
- M Cheema
- & A Sharif
-
Letter to the Editor
| Open AccessReply: ‘Hand pattern indicates risk of prostate cancer’
- A A Rahman
- , A Lophatananon
- & K-R Muir
-
Translational Therapeutics
| Open AccessIn vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines
- Z Adhim
- , T Matsuoka
- & T Shirakawa
-
Short Communication
| Open AccessSecond to fourth digit ratio (2D:4D) and prostate cancer risk in the Melbourne Collaborative Cohort Study
- D C Muller
- , G G Giles
- & G Severi
-
Molecular Diagnostics
| Open AccessIncreased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma
- R S Bhatt
- , A J Zurita
- & J V Heymach
-
Clinical Study
| Open AccessMeasurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis
- T Wu
- , E Giovannucci
- & S-M Ho
-
Translational Therapeutics
| Open AccessThiothymidine combined with UVA as a potential novel therapy for bladder cancer
- S W Pridgeon
- , R Heer
- & A V Boddy
-
Molecular Diagnostics
| Open AccessUpregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
- R Mukherjee
- , D H McGuinness
- & J Edwards
-
Epidemiology
| Open AccessOccupational exposure to dusts and risk of renal cell carcinoma
- S Karami
- , P Boffetta
- & L E Moore
-
Translational Therapeutics
| Open AccessInsulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel
- C C Uzoh
- , J M P Holly
- & C M Perks
-
Genetics and Genomics
| Open AccessPolygenic susceptibility to prostate and breast cancer: implications for personalised screening
- N Pashayan
- , S W Duffy
- & P Pharoah
-
Clinical Study
| Open AccessSorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
- G Procopio
- , E Verzoni
- & E Bajetta
-
Epidemiology
| Open AccessFluid intake and incidence of renal cell carcinoma in UK women
- N E Allen
- , A Balkwill
- & G Reeves
-
Translational Therapeutics
| Open AccessInhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
- J S P Yuen
- , M Y Sim
- & H Huynh
-
Molecular Diagnostics
| Open AccessLevels of circulating CD45dimCD34+VEGFR2+ progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
- F Farace
- , M Gross-Goupil
- & B Escudier
-
Letter to the Editor
| Open AccessReply: Choosing a stable housekeeping gene and protein is essential in generating valid gene and protein expression results
- D Revaud
- , J Caradec
- & S Loric
-
Molecular Diagnostics
| Open AccessExpression of NRG1 and its receptors in human bladder cancer
- J A Forster
- , A B Paul
- & M A Knowles
-
Molecular Diagnostics
| Open AccessThe tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer
- H Yoshino
- , T Chiyomaru
- & M Nakagawa
-
Clinical Study
| Open AccessDocetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
- R Petrioli
- , A Pascucci
- & G Francini
-
Translational Therapeutics
| Open AccessTargeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease
- B H Kang
- , M Tavecchio
- & D C Altieri
-
Mini Review
| Open AccessChallenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies
- M E Gore
- & J M G Larkin
-
Clinical Study
| Open AccessA multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol
- J Shamash
- , T Powles
- & T Oliver
-
Translational Therapeutics
| Open AccessTemsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
- Y Wang
- , X-Y Wang
- & H L Kim
-
Mini Review
| Open AccessSunitinib and other targeted therapies for renal cell carcinoma
- T Powles
- , S Chowdhury
- & T Hutson
-
Molecular Diagnostics
| Open AccessHuman prostate cell lines from normal and tumourigenic epithelia differ in the pattern and control of choline lipid headgroups released into the medium on stimulation of protein kinase C
- M Rumsby
- , J Schmitt
- & N Maitland
-
Molecular Diagnostics
| Open AccessERK5 signalling in prostate cancer promotes an invasive phenotype
- A K Ramsay
- , S R C McCracken
- & H Y Leung
-
Epidemiology
| Open AccessAssociation of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study
- P Dimitropoulou
- , R M Martin
- & D E Neal
-
Short Communication
| Open AccessAlcohol consumption and risk of renal cell cancer: the NIH-AARP diet and health study
- J Q Lew
- , W-H Chow
- & Y Park
-
Molecular Diagnostics
| Open AccessEnhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts
- A Shiirevnyamba
- , T Takahashi
- & H Uehara
-
Molecular Diagnostics
| Open AccessTumour suppressor microRNA-584 directly targets oncogene Rock-1 and decreases invasion ability in human clear cell renal cell carcinoma
- K Ueno
- , H Hirata
- & R Dahiya
-
Short Communication
| Open AccessHand pattern indicates prostate cancer risk
- A A Rahman
- , A Lophatananon
- & K Muir
-
Translational Therapeutics
| Open AccessSmall molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
- F R Lamont
- , D C Tomlinson
- & M A Knowles
-
Translational Therapeutics
| Open AccessAngiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?
- T Dolley-Hitze
- , F Jouan
- & C Vigneau
-
Genetics and Genomics
| Open AccessLY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling
- R Matsuda
- , H Enokida
- & M Nakagawa
-
Letter to the Editor
| Open AccessReply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib
- G H J Mickisch
- , B Escudier
- & M Nuijten
-
Epidemiology
| Open AccessScrotal cancer: incidence, survival and second primary tumours in the Netherlands since 1989
- R H A Verhoeven
- , W J Louwman
- & J W W Coebergh
-
Letter to the Editor
| Open AccessComment on ‘Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib’
- C Charbonneau
- & R Sandin
-
Clinical Study
| Open AccessA phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma
- J M G Larkin
- , T R Ferguson
- & M E Gore
-
Genetics and Genomics
| Open AccessWilms' tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways
- R T Sitaram
- , S Degerman
- & A Li
-
Translational Therapeutics
| Open AccessProlonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR
- A Schayowitz
- , G Sabnis
- & A M H Brodie
-
Clinical Study
| Open AccessSafety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
- T W Flaig
- , L J Costa
- & H Drabkin
-
Clinical Study
| Open AccessA phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
- J-F Rossi
- , S Négrier
- & B Berns
-
Genetics and Genomics
| Open AccessProstate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
- S M Edwards
- , D G R Evans
- & R A Eeles
-
Molecular Diagnostics
| Open AccessExpression of parvin-β is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract
- C-F Wu
- , K-F Ng
- & S-T Pang
-
Molecular Diagnostics
| Open AccessCo-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression
- J Hao
- , H Chen
- & Y Li
-
Molecular Diagnostics
| Open AccessInactivation of the WASF3 gene in prostate cancer cells leads to suppression of tumorigenicity and metastases
- Y Teng
- , M Q Ren
- & J K Cowell